Premium
Radionuclide therapy of adrenal tumors
Author(s) -
Carrasquillo Jorge A.,
PanditTaskar Neeta,
Chen Clara C.
Publication year - 2012
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.23196
Subject(s) - radionuclide therapy , medicine , paraganglioma , somatostatin receptor , pheochromocytoma , neuroendocrine tumors , somatostatin , neuroblastoma , targeted therapy , oncology , cancer research , endocrinology , pathology , cancer , biology , genetics , cell culture
Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I‐131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu‐177 or Y‐90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs. J. Surg. Oncol. 2012; 106:632–642. © 2012 Wiley Periodicals, Inc.